Welcome to our dedicated page for Lifemd SEC filings (Ticker: LFMDP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) provides access to regulatory documents filed by LifeMD, Inc., the issuer of this preferred security. These filings, drawn from the SEC’s EDGAR system, include current reports on Form 8‑K and other disclosures that reference both the company’s common stock and its 8.875% Series A Cumulative Perpetual Preferred Stock.
LifeMD’s Form 8‑K filings illustrate how SEC reports can inform investors in LFMDP. For example, the company has filed 8‑Ks describing changes in its independent registered public accounting firms, including the dismissal of prior auditors, the identification of material weaknesses in internal control over financial reporting, and the appointment of PricewaterhouseCoopers LLP. Other 8‑Ks discuss the release of financial results for specific periods and the furnishing of related press releases as exhibits.
These filings also show how LifeMD reports broader corporate events that may be relevant to preferred stockholders. The company has disclosed the divestiture of its majority interest in WorkSimpli Software LLC, positioning LifeMD as a pure‑play virtual care and pharmacy platform, and has described its focus on expanding virtual care and pharmacy offerings. In addition, press releases incorporated into filings and separate company announcements detail quarterly cash dividends authorized on the 8.875% Series A Cumulative Perpetual Preferred Stock, directly affecting LFMDP holders.
Through this page, users can review LifeMD’s filed balance sheets, statements of operations, and related notes where the Series A Preferred Stock is presented within the capital structure, including information about authorized and outstanding shares. Current reports also reference the preferred stock explicitly in the context of material events and exhibit listings.
Stock Titan enhances this raw filing data with AI‑powered summaries that explain the key points of complex documents in plain language. As new LifeMD filings are posted to EDGAR, they are updated on this page, allowing investors to quickly see how changes in auditors, internal controls, financial reporting, corporate transactions, or dividend decisions might relate to LFMDP. Users can also review filings that touch on executive appointments, compensation arrangements, and other governance topics that shape the environment in which the preferred stock exists.
Insider filing shows grant vesting and holdings Stefan Galluppi, Chief Innovation Officer of LifeMD, Inc. (LFMD), reported an acquisition on 08/22/2025 of 30,000 shares of common stock resulting from a performance stock grant that vested on that date. The reported price is $0, indicating these were shares issued on vesting rather than purchased. After the transaction, Galluppi directly beneficially owns 110,449 shares and indirectly beneficially owns 1,644,800 shares through American Nutra Tech, LLC. The Form 4 was signed on 08/26/2025.
LifeMD insider Jessica Friedeman acquired 50,000 shares of common stock upon vesting of performance stock on 08/22/2025. The Form 4 shows the transaction was reported on 08/26/2025 and lists Friedeman's role as Officer — Chief Marketing Officer. The filing reports 220,000 shares of common stock beneficially owned by the reporting person after the transaction. The acquisition is recorded as non‑derivative, with a reported price of $0 reflecting the vesting of previously granted performance stock.
LifeMD, Inc. reporting person Marc David Benathen, the company's Chief Financial Officer, had 87,000 shares of common stock become vested and were reported as acquired on 08/22/2025 at a reported price of $0, described as performance stock that vested. Following the transaction he beneficially owns 426,554 shares. The Form 4 is filed individually by the reporting person and lists the reporting person's address as LifeMD, Inc., 236 Fifth Avenue, Suite 400, New York, NY 10001.
LifeMD insider stock grant vested: Nicholas P. Alvarez, Chief Acquisition Officer of LifeMD, acquired 100,000 common shares on 08/22/2025 as a result of a performance stock grant that vested. The shares were issued at a $0 price, reflecting a vesting award rather than a purchased transaction. Following this vesting, Alvarez beneficially owns 680,000 common shares in total, held directly. The Form 4 was signed on 08/26/2025.
Insider Form 4 summary: Shayna Webb Dray, listed as Chief Operating Officer and a director-level reporting person at LifeMD, Inc., reported an acquisition on 08/22/2025 of 30,000 shares of the issuer's common stock through the vesting of performance stock. The transaction price is reported as $0, and following the vesting Dray beneficially owns 295,000 shares. The Form 4 was signed on 08/26/2025. The filing indicates the shares were granted as performance stock that vested on the transaction date.
LifeMD, Inc. reported another change in its independent auditor and highlighted ongoing internal control weaknesses. On August 15, 2025, with Audit Committee approval, the company dismissed CBIZ CPAs P.C., which had only been appointed in April 2025 and never issued an audit report.
On August 18, 2025, LifeMD appointed PricewaterhouseCoopers LLP (PwC) as its independent registered public accounting firm for the year ending December 31, 2025. The company states it has not previously consulted PwC on accounting or auditing matters. LifeMD also disclosed material weaknesses in internal control over financial reporting related to IT general controls, review of key third-party SOC reports, and business process controls over information produced by the company and evidence of formal review procedures.